Abstract | Macrophages are crucial drivers of tumour-promoting inflammation. Tumour-associated macrophages (TAMs) contribute to tumour progression at different levels: by promoting genetic instability, nurturing cancer stem cells, supporting metastasis, and taming protective adaptive immunity. TAMs can exert a dual, yin-yang influence on the effectiveness of cytoreductive therapies (chemotherapy and radiotherapy), either antagonizing the antitumour activity of these treatments by orchestrating a tumour-promoting, tissue-repair response or, instead, enhancing the overall antineoplastic effect. TAMs express molecular triggers of checkpoint proteins that regulate T-cell activation, and are targets of certain checkpoint-blockade immunotherapies. Other macrophage-centred approaches to anticancer therapy are under investigation, and include: inhibition of macrophage recruitment to, and/or survival in, tumours; functional re-education of TAMs to an antitumour, 'M1-like' mode; and tumour-targeting monoclonal antibodies that elicit macrophage-mediated extracellular killing, or phagocytosis and intracellular destruction of cancer cells. The evidence supporting these strategies is reviewed herein. We surmise that TAMs can provide tools to tailor the use of cytoreductive therapies and immunotherapy in a personalized medicine approach, and that TAM-focused therapeutic strategies have the potential to complement and synergize with both chemotherapy and immunotherapy. NATURE REVIEWS | CLINICAL ONCOLOGY VOLUME 14 | JULY 2017 | 399 REVIEWS © 2 0 1 7 M a c m i l l a n P u b l i s h e r s L i m i t e d , p a r t o f S p r i n g e r N a t u r e . A l l r i g h t s r e s e r v e d .
. Indeed, an inflammatory micro environment is now recognized to be an integral factor contributing to carcinogenesis -paradigms have shifted from a cancercellcentric view of carcinogenesis to one that encompasses the tumour microenvironment 3 . Therefore, suppression of effective anticancer immunity and tumourpromoting inflammation are now consid ered to be hallmarks of cancer. The formation of an inflammatory microenvironment within tumours can be driven by genetic events that cause cancer (aber rations involving oncogenes and tumoursuppressor genes), or by chronic nonresolving inflammatory con ditions, such as inflammatory bowel disease, which increase the risk of cancer development 1 . In general, cancerassociated inflammation is characterized as being nonresolving 5 .
Macrophages are a major component of the leukocyte infiltrate that is present, to a widely varying extent, in all tumours 6 . Dissection of the roles of tumour associated macrophages (TAMs) in tumour progression has paved the way to defining the contributions of other inflamma tory cells and mediators, such as inflammatory cytokines. In fact, TAMs have a dominant role as orchestrators of cancerrelated inflammation (CRI). The nature of the CRI associated with tumours arising in different tissues is highly diverse 2, 7 ; although the cellular components of CRI differ in phenotype and quantity, and the mediators that coordinate immune function can vary considerably across cancers, TAMs regulate a common inflammatory pathway that ultimately drives CRI 8 
.
In the 1970s, studies demonstrated that macrophages activated by bacterial products and cytokines acquire the capacity to kill tumour cells [9] [10] [11] . On the other hand, investi gators soon found that TAMs from malignant metastatic cancers promote tumour growth and metas tasis 12 . Thus, early evidence suggested that macrophages could engage in a dual yin-yang relationship with cancer.
Herein, we review the current understanding of the roles of TAMs in determining the effectiveness of differ ent anticancer treatment modalities, as well as emerging macrophagetargeting therapeutic strategies. A concise overview of the roles of macrophages in tumour initi ation and progression is provided as a foundation for this discussion; however, a detailed description of CRI and, specifically, the functions of myeloid cells in tumours is beyond the scope of this article, and these aspects have been extensively reviewed elsewhere 
Roles of TAMs in tumour progression
TAMs have long been hypothesized to originate from cells of the blood compartment, with chemotactic sig nals released from tumour cells or from nonmalignant cells present in the cancer microenvironment mediating recruitment of monocytic precursors to primary and metastatic tumour sites 11, [15] [16] [17] [18] [19] (FIG. 1a) ; however, accumu lating evidence calls this longheld view into question. In mice, resident macrophages in certain tissues (such as the microglia in the brain) originate from precursors that were seeded within the tissues during fetal and embryonic development, rather than from circulating monocytes 20, 21 (BOX 1). In gliomas, TAMs constitute a mixed cell popu lation that includes resident microglial cells, infiltrating blood monocytes, and macrophages 22 . The relative con tribution of these populations to tumour progression has been investigated in a genetically engineered mouse model of glioma: recruitment of circulating Ly6C hi 'inflamma tory' monocytes into tumour tissue was associated with an increased tumour incidence, decreased tumour latency, and shorter survival durations, with no contribution of microglial cells 22 . With regard to macrophage function in the tumour microenvironment, findings in mice indicate that the ontogenetic origin of TAM precursors does not have an appreciable effect on the macrophage phenotype that develops in response to tissuederived cues 23 . Whether tissue macrophages derived from embry onic precursors contribute to the number, location, and diversity of TAMs remains an open question 24 . Of note, TAM proliferation has been observed in mouse models of sarcoma, and in mouse and human breast carcinomas, but this general mechanism does not seem to sustain the numbers of TAMs in growing tumours [25] [26] [27] , suggesting that recruitment of circulating cells is required to main tain the TAM population. Circulating precursors that are recruited into tumour tissues and subsequently differenti ate into TAMs include conventional inflammatory mono cytes and monocyterelated myeloidderived suppressor cells (MMDSCs; BOX 1; FIG. 1a) . Downregulation of the transcription factor STAT3 is a key process mediating the differentiation of MMDSCs into mature TAMs 28 .
In addition to contributing to the immunosuppressive tumour microenvironment, MMDSCs are direct pro moters of tumour metastasis 29 . Inflammatory monocytes, defined in mice as Ly6C + /CCR2 + cells, have been shown to contribute to TAM accumulation and maintenance in a mouse mammary tumour model 27 , and to the establish ment of pulmonary metastases derived from mouse or human breast cancer cells 19 . The differentiation of mouse inflammatory monocytes into TAMs is dependent on RBPJ (a transcriptional regulator of Notch signalling), and genetic deletion of this protein in TAMs reduces tumour burden in a mouse breast cancer model, indicating the nonredundant function of monocytederived TAMs in supporting tumour growth 27 . By contrast, a protective role of Ly6C − /CX3CR1
+ 'nonclassical' patrolling mouse monocytes has been demonstrated. These cells, the differenti ation of which is driven by the transcription factor NR4A1, patrol the lung microvasculature under steadystate conditions, but rarely extravasate into tis sues and differentiate into macro phages; however, they rapidly accumulate within lung metastases, and inhibit tumourcell seeding and growth in mouse models 30 . The antitumour functions of these nonclassical monocytes include scavenging of tumour debris, and recruitment and activation of natural killer (NK) cells 30 . Chemoattractants involved in monocyte recruit ment include chemokines (such as CCL2 and CCL5), and cytokines (for example, CSF1 and members of the VEGF family). TAMs themselves can be a source of CCL2 in cancer 1, 5 . Genetic evidence from mouse models indicates that complement components, particularly C5a, are also important mediators of the recruitment and functional polarization of TAMs 31 . Indeed, such chemotactic factors act as more than attractants because they activate transcriptional programmes that contribute to the functional skewing of macrophages towards spe cific phenotypes 32 . CSF1, in particular, is a monocyte attractant as well as a macrophage survival and polar ization signal that drives TAM differentiation towards an immunosuppressive, tumourpromoting 'M2like' phenotype 6, 33 
. Unlike CSF1, GMCSF activates macrophage functions related to antitumour activity 34 . Signals originating from tumour cells, T lympho cytes and B lymphocytes, and stromal cells influence TAM function and diversity. Classically activated 'M1' macro phages (BOX 1) can kill tumour cells via extra cellular mechanisms and thereby mediate tissue destructive reactions involving the walls of blood vessels (haemor rhagic necrosis) [9] [10] [11] 15 . Accordingly, evidence indicates that, in nascent tumours, macrophages contribute to the early 'elimination' phase of immunoediting orches trated by T cells and interferons 35 . Subsequently, tumour progression is associated with skewing and subversion of macrophage function -in line with the 'equilibrium' and 'escape' phases of cancer immunoediting. In estab lished, progressive tumours, such as mouse and human breast or pancreatic cancers, IL4 and IL13 derived from type 2 Thelper (T H 2) cells [36] [37] [38] , eosinophils 39 , or basophils 40 elicit alternative M2 activation of TAMs FIG. 1b) . In addition, signals originating from tumour cells (such as chemokines, CSF1, and TGFβ),
Key points
• Tumour-associated macrophages (TAMs) are a key component of the cancer microenvironment, and influence tumour growth and progression • TAMs can have a dual supportive and inhibitory influence on cancer, depending on the disease stage, the tissue involved, and the host microbiota • TAMs can limit the antitumour activity of conventional chemotherapy and radiotherapy by orchestrating a tumour-promoting repair response to tissue damage, and by providing a protective niche for cancer stem cells • Conversely, TAMs contribute to the antitumour activity of selected chemotherapeutic agents, such as doxorubicin (under certain conditions), and of monoclonal antibody therapies via antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP) • Of note, macrophage depletion has a key role in the antitumour activity of the clinically approved anticancer agent trabectedin • Therapeutic strategies targeting macrophages as tumour-promoting factors, and/or aimed at macrophage activation and re-education are undergoing clinical assessment; such strategies have the potential to complement cytoreductive, antiangiogenic, and immune-checkpoint-inhibitor treatments B cells (immune complexes), and stromal cells (for example, IL1) can cause phenotypic shifts in macro phages 8 , imparting diverse functions that do not fit with those ascribed to classic M1/M2polarized cell types
. Indeed, evidence indicates that the rela tive impor tance of distinct pathways of macrophage differentiation varies between different tumours, resulting in hetero geneous TAM phenotypes and functions 2, 7 . Moreover, distinct populations of TAMs within a given human or mouse tumour can also exhibit different pheno types as a result of, for example, disparities in access to oxygen and activation of the HIF pathway [41] [42] [43] (FIG. 1b) . At present, dissecting TAM diversity at the single cell level and integrating this information remains challen ging. In spite of the phenotypic plasticity of TAMs and the associated intratumour and intertumour diversity in CRI, ultimately, TAM polarization toward an immuno suppressive phenotype seems to be a common feature of most cancers. TAMs in progressing neoplasms typ ically express characteristic surface molecules, such as the haemo globin scavenger receptor CD163 and macro phage mannose receptor 1 (also known as CD206) 44, 45 , and demonstrate properties related to stimulation of angiogenesis, suppression of adaptive immunity, and promotion of cancer growth and metastasis [6] [7] [8] . In line with a consensus recommendation 34 , we limit use of the 'M2' designation to settings in which IL4 or IL13 are major drivers of macro phage polarization; for simplicity, we and others refer to the diverse immunosuppressive TAM populations as 'M2like'
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TAMs influence the intrinsic properties of tumour cells, as well as those of the tumour micro environment (FIG. 1c) . For example, TAMs produce growth fac tors, such as EGF, which stimulates proliferation of breast carcinoma cells [1] [2] [3] [4] [5] 11, 17 . By producing proteolytic enzymes that digest the extracellular matrix, TAMs also pave the way to tumourcell dissemination from the primary tumour site, thereby contributing to meta stasis. Moreover, macrophages produce factors, such as IL1, that promote the accumulation of tumour cells at distant sites, and TAMs present at metastatic sites can provide a supportive niche for metastatic cells 1, 6, 8 . In addition, reactive oxygen and nitrogen inter mediates generated by TAMs contribute to cancercell genetic instability 31 -a hallmark of cancer that limits the effectiveness of chemotherapy and targeted therapies. Furthermore, TAMs promote angiogenesis and lympho angiogenesis, as well as tissue remodelling, for example, by stimulating the deposition of fibrous tissue 1, 46, 47 . All of these processes can support tumour development and progression.
Myelomonocytic cells also contribute to the suppres sion of effective adaptive immunity -a key feature of cancer 3 -at various levels and through multiple mech anisms. MDSCs, and in particular MMDSCs, suppress the development of antitumour immunity in lymphoid organs, as well as immune effector responses in the tumour itself 29, 48 . TAMs can also promote the immuno suppressive activity of regulatory T (T reg ) cells through a bidirectional interaction 15 (FIG. 2) . With regard to the mechanisms underlying these effects, in the tumour context, macrophages produce immunosuppressive cytokines (IL10 and TGFβ) 6, 7 . In addition, the profile of amino acid metabolism by M2 or M2like macrophages and TAMs results in metabolic starvation of T cells owing to the activity of arginase and/or the production of immunosuppressive metabolites via the indoleamine 2,3dioxygenase (IDO) pathway 34 . Moreover, prosta glandins produced by TAMs via arachidonic acid metabolism have immunosuppressive effects 14 . Finally, TAMs often express PDL1 and PDL2, which trigger the inhibitory PD1mediated immune checkpoint in T cells, as well as B7H4 (REF. 49 ) and VISTA 50 , which might have similar functions (FIG. 2) .
Progress has been made in defining the molecular pathways involved in orchestration of macrophage func tion in tumours, including members of the STAT and NFκB family 8 . Among these, MYC is interesting in that it mediates the tumorigenic mechanisms of both cancer cells and macrophages. Expression of the MYC onco gene accounts of approximately 40% of the transcrip tional fingerprint of human M2macrophage activation, and MYC is overexpressed in human TAMs 51 . In cancer cells, the oncogenic protein MYC has been shown to induce expression of the 'don't eat me' signal CD47, and the immunecheckpoint protein PDL1 (REF. 52); thus, expression of MYC seems to enable tumour cells to suppress innate immunity in the form of macrophage mediated phagocytosis, via CD47 expression, as well as activation of effective adaptive antitumour immunity, through induction of PDL1 expression.
Box 1 | Diversity and nomenclature of myelomonocytic cells
Diversity and plasticity are both hallmarks of cells of the monocyte-macrophage lineage 20, 21, [193] [194] [195] . In general, considerable differences exist between mice and humans in terms of markers defining monocyte-macrophage diversity. In humans, circulating monocytes, which originate from bone-marrow precursors, can be classified into two main subsets based on expression of CD14 48, 57 . MDSCs are heterogeneous, being related to either monocytes (M-MDSCs) or neutrophils (PMN-MDSCs); both subtypes express the immature myeloid-cell marker CD33, but only M-MDSC express this marker at high levels 57 . M-MDSCs can infiltrate tumours and differentiate into tumour-associated macrophages (TAMs) 57 . Tissue macrophages originate either from embryonic precursors that seed peripheral locations and self-sustain over the lifetime of the host, or from circulating monocytes 21, 196 . In tissues, cells of the monocyte-macrophage lineage undergo diverse forms of functional reprogramming in response to different signals 10, 11, 15 . In particular, bacterial products and interferons (IFNs), produced during type 1 immune responses driven by type 1 T-helper (T H 1) cells and type 1 innate lymphoid cells (ILCs), activate the tumour-cell killing and tissue-damaging properties of these cells. Cytokines produced during type 2 immune responses driven by type 2 ILCs and type 2 T-helper (T H 2) cells, such as IL-4 and IL-13, activate an alternative form of macrophage activation oriented to resistance against parasites, and to tissue repair and remodelling. Mirroring immunological nomenclatures in current usage (such as 'T H 1' and 'T H 2'), these two alternative forms of macrophage activation are often referred to as M1 (or classic) and M2 (or alternative). The extremes and continuum between the M1 and M2 phenotypes do not, however, recapitulate the full spectrum of macrophage plasticity; indeed, similar plasticity and flexibility of ILCs and T-cell phenotypes is now recognized. Such nomenclature issues in immunology have been discussed extensively elsewhere 34, 197 . In neoplastic tissues, the signals orchestrating macrophage function are diverse and vary considerably between different tumours, or even different parts of the same tumour, resulting in varied TAM phenotypes, which in many cases do not fit the M1/M2 classification. We and others use 'M1' to concisely refer to macrophage phenotypes driven by IFNγ and bacterial products, and 'M1-like' to include those polarization states leading to antitumour responses and cytotoxicity, such as that induced by GM-CSF. We use 'M2' to concisely refer to macrophage phenotypes driven by IL-4 or IL-13 (REF. 34 ), and 'M2-like' to encompass a gamut of diverse phenotypes that share the functional outputs of tumour promotion and suppression of effective adaptive immunity. The inherent imperfection and limited utility of these oversimplified nomenclatures have been discussed elsewhere 197 .
The biomarker potential of TAMs Studies investigating the prognostic significance of TAMs have relied on a variety of methodological approaches, ranging from morphological identification in early efforts 11 to geneexpression profiling 53 . The most extensively used human macrophage marker is CD68, a panmacrophage marker; however, CD68 can occasionally be expressed in stromal cells as well as in cancer cells themselves; therefore, use of this marker to identify TAMs necessitates the careful evaluation of the data obtained 54 . In many studies, CD163 (which is associated with M2like polarization of macrophages), CD204 (also known as macrophage scavenger recep tor A), and CD206 (expression of which is induced by IL4) have been used to detect TAMs, with overall results comparable to those obtained using CD68 (REFS 44, 45) . In addition, a range of other molecules have been used to characterize TAMs, including stabilin1 (which is a scavenger receptor and adhesion molecule expressed by M2polarized macrophages and TAMs 55 ), chemo kines and/or chemokine receptors (such as CCL17) 45 , and cytokines and/or cytokine receptors (for example, IL10 and IL12) 45 . M1like macrophages polarized with IFNγ, which have antitumour activity, usually express high levels of HLADR 44 and, thus, this marker has been exploited to detect macrophages with an antitumour pheno type; however, HLADR is widely expressed in other leukocyte populations.
Different approaches are used for the identifica tion of circulating macrophage precursors, such as monocytes and MMDSCs, in patients or animals with cancer: these cell types are commonly investigated using multicolour flow cytometry of blood samples -rather than the immunohistochemical methods typically used to detect TAMs in tumour specimens. Monocyte populations detected using flow cytometry are referred to as 'inflammatory ' 29 . Macrophages infiltrating mouse and human tumours show considerable diversity within a given cancer, depending on their microanatomical locali zation 42, 55 ; as alluded to previously, hypoxia is a major driver of macrophage diversity within tumours 13, 56 . Thus, an inherent limitation of available data on the predictive value of TAMs is that the intratumour diversity of these cells has not usually been accounted for.
For many types of solid tumours, a high degree of macrophage infiltration has long been associated with a poor patient prognosis 57 . These observations pro vided a foundation for the now widely accepted view that TAMs promote tumour progression, as discussed above. In patients with breast carcinoma, macrophage infiltration has been associated with tumour grade, a lack of hormonereceptor expression, the basallike disease subtype, and an unfavourable outcome 26 . TAM density is also positively correlated with more advanced stage disease at diagnosis in patients with breast or blad der cancer 46, 58 , whereas a negative correlation has been reported in patients with ovarian or gastric cancer 59, 60 . The overall negative prognostic significance of TAM infiltration across all solid tumour types studied to date has been confirmed in a metaanalysis by Zhang et al. 61 that included all of the available data.
In apparent contrast with these findings, in patients with certain tumour types (nonsmallcell lung cancer 62 , prostate cancer 63 , and colorectal cancer (CRC) 64 ), a high degree of macrophage infiltration (typically defined as densities above the median, or in the highest quartile in each cohort) has been associated with a favourable prognosis. In CRC, this observation was confirmed in the metaanalysis conducted by Zhang et al. 61 , and also in an analysis of 209 patients with CRC treated at our institution (Malesci, A. et al., unpublished data). Interestingly, a high density (above the median value) of neutrophil infiltration into CRCs has also been associated with favourable patient survival 65 . In these settings, the favourable prognostic significance of macrophage infil tration is probably related to the positive effects of TAMs on response to chemotherapy.
Despite evidence of intratumoural TAM proliferation observed in some mouse models 25 , whether or not TAMs proliferate in situ within human tumours remains less clear. In one study, however, PCNA + cells were identi fied as proliferating macrophages in human breast car cinoma specimens. The presence of these proliferating TAMs was associated with hormonereceptornegative disease, a basallike subtype, and worse outcome than that of patients without evidence of TAM prolifera tion 26 . These findings warrant investigation of the pres ence of PCNA + TAMs within other tumour types and, if detected, assessment of their prognostic significance.
In patients with classic Hodgkin lymphoma (CHL), a gene signature of TAMs and a high number of CD68 + cells in the tumour have been associated with shortened survival durations after treatment with chemotherapy regimens, compared with that of patients without these characteristics; therefore, TAMs have been proposed as a biomarker for risk stratification 66 (TABLE 1) . High CD68 or CD163 expression have subsequently been confirmed to be independent predictors of unfavour able survival in the multicentre, randomized, controlled, E2496
Intergroup trial 67 , thus reinforcing the prognostic signifi cance of TAMs in chemotherapytreated patients with locally extensive and advancedstage CHL.
Previously, tumours with a high TAM (CD68 + cell) content had also been associated with unfavourable outcomes in patients with follicular lymphoma treated with multiagent chemotherapy 68, 69 . This prognostic association is reversed, however, in patients treated with the RCHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) regimen 70 . Results of an independent study confirmed that high TAM (CD163 + cell) numbers were predictive of a favourable outcome in patients with follicular lym phoma who received RCHOP immunochemotherapy, Positively correlated with DFS (P <0.001) 5 -FU, 5-fluorouracil; ABVD, doxorubicin, bleomycin, vinblastine, and dacarbazine; BP-VACOP, bleomycin, cisplatin, etoposide, doxorubicin, cyclophosphamide, vincristine, and prednisone; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; CVP, cyclophosphamide, vincristine, and prednisone; CVPP, cyclophosphamide, vinblastine, procarbazine, and prednisone; DFS, disease-free survival; DSS, disease-specific survival; GDP, gemcitabine, dexamethasone, and cisplatin; HPF, high-power field; OS, overall survival; TAM, tumour-associated macrophage. *Or ABVD-like, with or without radiation therapy. Second-line therapy comprised autologous stem-cell transplantation, CVPP or GDP chemotherapy, and/or field radiation. ‡ 5-FU and folinic acid plus oxaliplatin (FOLFOX) adjuvant chemotherapy is the standard-of-care for stage III colorectal cancer. § CLEVER-1 and stabilin-1 were used as a marker of alternatively activated M2 macrophages.
but, conversely, were associated with an adverse outcome in patients treated with rituximab, cyclophosphamide, vincristine, and prednisone (RCVP) 71 . Doxorubicin is the drug that differentiates the RCHOP regimen from the RCVP regimen; therefore, the parallelism between these clinical observations and early preclinical data sup porting a role of TAMs in determining the antitumour efficacy of doxorubicin in a mouse lymphoma model is striking 72 . These findings not only confirm that TAM numbers are predictive of outcome in patients with folli cular lymphoma, but also underscore that their prognos tic value is dependent on treatment. Nowadays, unlike in the past, patients with neoplastic conditions typically receive pharmacological anticancer treatments, thus the prognostic value of a variable is meaningless unless related to the administered treatment (that is, the vari able acquires predictive rather than purely prognostic value). Considering that patients with lymphoma usually receive multiple lines of treatment, one might conclude that TAMs can serve as predictive biomarkers in this setting, and are positively or negatively correlated with outcome depending on the type of chemotherapy used.
Data from patients with solid tumours on the pre dictive potential of TAMs are limited. Most studies assessing the prognostic value of TAMs do not report the adjuvant therapy regimens used, even when such treatments are considered an international standard of care 55, 73, 74 . The only published comparison of the associ ation of TAMs with outcome in patients who received chemotherapy after solid tumour resection versus those who did not was focused on pancreatic cancer, and indi cated a dual effect of these cells depending on whether adjuvant chemotherapy was used 45 . Specifically, a high TAM density seemed to be a critical determinant of responsiveness to adjuvant gemcitabine treatment, which negated the negative prognosis associated with high TAM numbers in patients who did not receive adjuvant chemotherapy 45 . In parallel, high TAM den sities have been associated with favourable outcomes in patients with stage III CRC who received adjuvant 5fluorouracilbased chemotherapy, but not in untreated patients (Malesci, A. et al., unpublished data). These studies support the role of TAMs as predictive factors of responsiveness to postsurgical chemotherapy, rather than only as prognostic indicators.
Effects of TAMs on treatment responses
Yin-yang effects of chemo/radiotherapy. Chemotherapy can affect macrophage function directly or indirectly, with the latter route primarily involving their modulation of adaptive immune responses, and thus ultimately influ encing the outcome of therapy (FIG. 2) . Data from a num ber of studies highlight that different chemo therapeutic agents have varying interactions with immunity. Indeed, an interaction between the antitumour actions of chemo therapeutic agents, such as actino mycin D, and human and murine monocytes/macrophages, was reported more than 30 years ago, as a phenomenon termed 'drugdependent cellular cytotoxicity' (REF. 75 ). Moreover, data from an even earlier study revealed that immunity plays a key part in determining the ultimate efficacy of doxorubicin 72 . Morerecent reports 76, 77 have demonstrated that, in response to selected chemo therapeutic agents, particularly doxorubicin, tumour cells undergo immunogenic cell death -that is, they express alarm signals that trigger effective adaptive immune responses. For instance, in a mouse model, exposure to doxo rubicin causes tumour cells to release ATP, which leads to recruitment of mononuclear phago cytes 78 ; under these conditions the infiltrating myeloid cells differentiate into antigenpresenting cells that trigger effective adaptive immune responses 78 .
The host microbiota has emerged as an impor tant determinant of the efficacy of chemotherapy and immuno therapy in mouse models [79] [80] [81] . For example, priming of myeloid cells by microbiota components is essential for the antineoplastic efficacy of platinum combined with adjuvant CpG oligonucleotides in mouse tumour models 79 . In the same vein, the anti neoplastic activity of anthracyclines is compromised in mice with genetic inactivation of the formyl peptide receptor 1 (FPR1), a sensor of microbial components and tissue damage that is expressed in myeloid cells 82 . Of note, the presence of a lossoffunction FPR1 allele has been associated with unfavourable survival in patients with breast carcinoma or CRC after adjuvant chemotherapy 82 . Indeed, data from preclinical models suggest that myeloid cells determine the role of immu nity in the antitumour activity of selected chemothera peutic agents 77 , which can be leveraged to increase the efficacy of immune checkpoint inhibition 83 . In mouse models, repolarization of macrophages has also been reported in the context of targeted therapy, such as treat ment of KITpositive gastrointestinal stromal tumours (GISTs) with imatinib 84 , and treatment of hepatocellular carcinoma with sorafenib 85 . Trabectedin, which is approved by the EMA for the treatment of softtissue sarcomas and ovarian cancer, and by the FDA for sarcoma therapy, is a DNAbinding agent that causes DNA damage and cellcycle arrest in tumour cells; however, this 'conventional' effect accounts for only part of the drug's complex mechanism of action. By interacting with DNAbinding proteins, trabectedin affects the transcription of selected genes, including some that encode inflammatory cytokines and chemokines, as well as angiogenic factors 86 . Clinical observations of delayed but prolonged responses after trabectedin treatment are inconsistent with the anti tumour activity of this agent being mediated only by effects on cancer cells. This experience has prompted analyses of the effects of this drug on immunity 87, 88 . Trabectedin has been found to trigger activation of caspase 8, the key effector molecule of the extrinsic apoptotic pathway (programmed cell death activated via cellsurface receptors), selectively in monocytes, indu cing their apoptotic death. In preclinical models, deple tion of macrophage numbers has been demonstrated to be a key mechanism mediating the antitumour activity of this compound 87 . Furthermore, reduced TAM infiltration and decreased angiogenesis have both been observed in tumour samples from patients with sarcoma treated using trabectedin, compared with pretreatment biopsy samples 87 . Thus, preclinical and clinical evidence suggests that a reduction in macro phage numbers is a key component of the antitumour activity of trabectedin.
Macrophages do not, however, have a universally positive effect on responsiveness to chemotherapy. M2 and M2like polarized macrophages orchestrate tissue repair. Consistent with this general property of cells of the monocyte-macrophage lineage, evidence indicates that, under selected conditions, TAMs can limit the effectiveness of cytotoxic agents (FIG. 3) . These agents include platinumcontaining compounds, pacli taxel, and also doxorubicin 33, [89] [90] [91] [92] [93] . In mouse tumour transplantation models, M2like macrophages were found to accumulate in perivascular areas of the tumour after chemotherapy, and promoted tumour revasculari zation and relapse 94 ; recruitment of these cells was found to be CXCR4-CXCL12 dependent 94 . The apparent discrepancy in the role of TAMs in mediating the response to doxorubicin 72,89-93 probably reflects differences in the mouse tumour models used (for instance, in terms of immunogenicity). As discussed, however, a high degree of TAM infiltration is associated with favourable prognosis in patients with lymphomas treated with doxorubicincontaining regimens 71 , mirror ing preclinical data 72 . The positive interaction between chemotherapy and macrophagemediated host defense is also reflected in the prognostic and/or predictive significance of TAMs in pancreatic cancer 45 and CRC (Malesci, A. et al., unpublished data). Mirroring these clinical associations, gemcitabine was found to synergize with macrophages in tumourcell killing in vitro 45 . 92, 93 . Indeed, macrophages are an essential component of the stemcell niche in a variety of tissues. Thus, the dark side of the interaction of chemotherapy with TAM is a reflection of the fundamental properties of macrophages -that is, their roles in the tissue stemcell niche, in taming adaptive immunity, and in orchestrating repair responses.
Similar to the effects of chemotherapy, the effects of radiotherapy on myeloid cells can have dual impli cations for patient outcomes. In mouse models, the influx of monocytes into tumours following radio therapy drives a profibrotic tissue response and might promote tumour recurrence 8, 95 . Conversely, in patients, tumour regression at sites distant from the irradiated lesions -termed the 'abscopal' effect 96 -could plau sibly be explained by activation of host anticancer immunity. In a mouse model, neoadjuvant lowdose γirradiation was found to set macrophage functions to an antitumour mode characterized by a lack of both immunosuppressive and pro angiogenic activity, and the production of Tcellattracting chemokines 97 . Therefore, TAMs can either reduce or amplify the magnitude of the antitumour effect of radiotherapy depending on context.
Influence on hormonal therapy. Evidence suggests that two classic pathways that promote tumour devel opment and growth, inflammation, and hormone sig nalling via sex steroids, are linked 1 . In prostate cancer cells, IL1β produced by macrophages triggers a switch in the activity of selective androgen receptor modulators (SARMs), from inhibitory to stimulatory 98 . In prostate cancer specimens from patients who had been treated with androgen blockade therapy, a high TAM den sity (above the observed median value) was associated with an increased recurrence rate 99 . Of note, androgen blockade therapy induced production of macrophage attracting cytokines, particularly CSF1, by tumour cells in a preclinical prostate cancer model 100 . In this model, inhibition of the tyrosine kinase activity of the CSF1 receptor (CSF1R) had synergistic antitumour activity with androgen blockade 100 . Thus, targeting TAMs might amplify the susceptibility of prostate cancer cells to hormonal interventions.
Roles in antiangiogenic therapy. Strategies targeting VEGF signalling are part of the current therapeutic armamentarium in oncology. In addition to eliciting angiogenesis, VEGF is a potent attractant of mono cytes, acting via VEGFR1 (REFS 101, 102) . Interestingly, in a mouse mammary carcinoma model, Qian et al. 102 found that expression of VEGFR1 is upregulated in metastasis associated macrophages. VEGF has long been Nature Reviews | Clinical Oncology known to be chemotactic for monocytes in this model; however, this cytokine did not drive the accumulation of macro phages within metastases. Instead, VEGF signal ling was found to activate an autocrine CSF1mediated feedback pathway in metastasisassociated macrophages that underlies their tumourpromoting activity. Indeed, macrophages, including TAMs, are a major source of angiogenic growth factors, including VEGF, that act on vascular and lymphatic vessels 13 . Correspondingly, TAM density and vascular density are generally closely correlated in human tumours 1, 46, 47 . Moreover, resistance of tumours to current antiVEGF therapies is frequently associated with high levels of myeloidcell infiltration 56 . Preclinical evidence suggests that hypoxia resulting from destruction of the vascu lar bed, as a consequence of antiangiogenic treatment, triggers compensatory recruitment of myeloid cells that promote angiogenesis via alternative mechanisms to those targeted therapeutically, such as via production of thymidine phosphorylase, Bv8, and cathepsin B 8, 13, 47, 103 . Angiopoietin2 (ANG2) is a regulator of vesselwall integrity that is functionally linked to angiogenesis and TAM function. In addition to providing an escape path way from VEGF inhibition, ANG2 can activate a pro angiogenic phenotype in macrophages 104 . Macrophage infiltration into human glioblastomas is correlated with a poor prognosis, and this tumour type is resistant to antiVEGF therapy. In preclinical models of this disease, a bispecific antiANG2/VEGF antibody has appre ciable antitumour activity and reprogrammes TAMs from a protumour M2 phenotype to an antitumour M1 phenotype 105, 106 . Thus, targeting TAMs might comple ment current antiangiogenic therapies and improve the effectiveness of this treatment.
Skewing and suppression of T-cell responses
Influence on immune-checkpoint blockade. Immuno therapy using immunecheckpoint inhibitors is becoming an established part of the therapeutic arma mentarium for an increasing number of cancers 107 . Clinically validated targets include CTLA4, PD1, and PDL1, and others are undergoing clinical evalu ation. Myelomonocytic cells are a key component of the immuno suppressive pathways targeted by immunecheckpoint inhibitors, and might, therefore, offer tools to predict or increase the activity of such treatments. For example, macrophages can express the PD1 ligands PDL1 and PDL2, as well as the CTLA4 ligands B71 (CD80) and B72 (CD86), and the related protein B7H4 (which interacts with an as yet unidenti fied immunecheckpoint receptor on T cells). PDL1 and PDL2 are upregulated on the surface of macrophages in response to various stimuli, including cytokines and hypoxia 108, 109 . TAMs present in a variety of human tumour types, such as hepatocellular carcinoma 110, 111 , glioblastoma 112 , and pancreatic cancer 113 , express high levels of PDL1 and/or B7H4. How, and to what extent, the expression of PDL1 (and/or PDL2) and B7H4 on macrophages contributes to the immunosuppres sive function of this cell type has not been fully eluci dated. Nevertheless, the expression of these triggers of inhibitory immune checkpoints by TAMs needs to be carefully assessed as a predictor of response to therapy, particularly to immunecheckpoint blockade 114, 115 . Analysis of the mode of action of CTLA4blocking monoclonal antibodies (mAbs) has revealed an un expected role of TAMs. In preclinical models, FcγR expressing macrophages eliminated CTLA4positive, mAbcoated T reg cells from tumours via antibody dependent cellular cytotoxicity (ADCC) 116, 117 ; the TAMmediated removal of T reg cells unleashed effec tive antitumour immunity. The role of macrophage mediated ADCC in the activity of the antiCTLA4 mAb ipilimumab has been examined in 15 patients with mela noma who responded to this agent and 14 matched 'nonresponders' (REF. 118); responders had higher num bers of peripheral blood CD16 + monocytes and, upon treatment, a higher CD68 + /CD163 + macrophage ratio (used as a correlate of M1 skewing) at tumour sites. Moreover, responses to ipilimumab were associated with a decrease in T reg cell densities within the tumour at 4 weeks after treatment 118 . In general, however, macrophages contribute to the immunosuppression observed in the tumour micro environment through multiple mechanisms (FIG. 2) ; therefore, targeting of TAMs might complement the action of immunecheckpoint inhibitors by remov ing additional inhibitory factors that might continue to restrain the action of T cells in spite of checkpoint blockade. Indeed, in a model of pancreatic cancer, inhib ition of CSF1signalling synergized with checkpoint blockade immunotherapy 89, 119 . Combination therapies with mechanisms of action based on this principle are undergoing early clinical evaluation (TABLE 2) .
Contributions to antibody therapies. Phagocytosis is a fundamental mechanism of innate resistance against microorganisms and of effete (aged and/or dam aged) cell disposal (specifically termed effero cytosis). Historically, many researchers hypothesized that phago cytosis is not an important process underlying the anti tumour activity of activated macrophages, and that mechanisms of extracellular killing are more relevant to macrophagemediated killing of cancer cells 10 . Evidence has now challenged this longheld view, spurring interest in the clinical implications of tumourcell phagocytosis.
The CD47-SIRPα pathway has an important role in regulating phagocytosis, which in turn is a key fac tor in tissue homeostasis. Both SIRPα and CD47 are members of the immunoglobulin superfamily, and are expressed on macrophages and candidate target cells, respectively [120] [121] [122] . Upon binding to CD47, SIRPα acts as a docking protein for the SHP1 and SHP2 phosphatases, which dampen intracellular signalling, and thereby negatively regulates phago cytosis. Thus, CD47 acts physio logically as a 'don't eat me' signal. Of note, CD47 is frequently overexpressed by cancer cells 120, 121, 123, 124 . Masking of CD47 on cancer cells using mAbs or an engineered soluble SIRPα-Fc construct can trigger antibodydependent cellular phagocytosis (ADCP) of tumour cells in vitro, and antiCD47 mAbs have antitumour activity in diverse mouse models 120, 121, [123] [124] [125] . Such agents have now entered clinical testing (TABLE 2) . Solid tumours Gemcitabine, paclitaxel and carboplatin
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Importantly, CD47targeting agents have proven synergy with diverse antitumour mAbs, including antiCD20 and antiHER2 antibodies 116, 117, [119] [120] [121] 126 . These findings are consistent with the ability of SIRPα to downregulate FcγR signalling in macrophages 120, 121 . Interestingly, antiCD47 mAb treatment was found to prime adaptive antitumour immune responses in mouse models, either directly or via activation of acces sory cell function 127, 128 . Indeed, the ultimate efficacy of CD47 blockade in the B16F10 mouse melanoma model requires activation of an adaptive immune response, as demonstrated by the need for additional PDL1 block ade in order to achieve durable antitumour immunity 129 . Of note, CD47 has been found to be highly expressed on pancreatic CSCs, and targeting of this protein not only promoted phago cytosis of these cells by macro phages, but also directly induced cancer cell apoptosis in the absence of macro phages. Moreover, although antagonism of CD47 did not have relevant antitumour activity in a patient derived xenograft model, such treat ment resulted in synergistic antitumour activity when combined with chemotherapy 130 . For four decades, macrophages have been known to kill tumour cells extracellularly via ADCC 131 . In fact, ADCC, which can be mediated by NK cells in addition to macrophages, is an essential component of the activity of antitumour mAb therapies, including those targeting CTLA4, CD20, HER2 and EGFR 118, 132 . Polymorphisms in the genes encoding FcγRIIIA and FcγRIIA are correlated with responsiveness of patients with lymphoma to rituxi mab (an antiCD20 antibody), those with colon cancer to cetuximab (an antiEGFR antibody), and women with breast carcinoma to trastuzumab (an antiHER2 anti body) [133] [134] [135] . FcγRIIA is only expressed in platelets, macro phages and neutrophils; however, only macrophages are potent effectors of ADCC and, therefore, these data suggest an important role of these immune cells in the clinical activity of mAbbased treatments. In a preclinical lymphoma model, the antitumour activity of rituximab has been shown to be dependent on chemokine mediated macro phage recruitment and on macrophage effec tor functions 136 . Interestingly, signals that skew TAM function to an M2like phenotype (IL10 and CSF1), and are potentially present in the tumour microenviron ment, have been found to enhance macrophage mediated phagocytosis of rituximab opsonized lymphoma cells 137 . Consistent with these observations, although high TAM density has been associ ated with an unfavourable prog nosis in lymphoma 68 , high TAM infiltration was associ ated with a favourable outcome in patients treated with rituximabcontaining regimens 70 . Similarly, in a breast cancer model, TAMs promoted tumour growth, but were essential for the thera peutic efficacy of a mAb targeting CD142 (REF. 138 ), as well as trastuzumab 126 . Thus, find ings from preclinical models, mechanistic analyses, and clinical correlative studies indicate that the functional activation of TAMs can promote antibody dependent macrophage effector functions and might be beneficial to anticancer therapy.
Agents that enhance TAMmediated ADCC and ADCP could potentially be used in combination approaches with immunogenic chemotherapy, which stimulates macrophage recruitment, activation, and/or effective antitumour immunity. For example, in a mouse model of Bcell acute lymphoblastic leukaemia, cyclo phosphamidemediated tissue damage elicited macro phage recruitment via the release of chemokines and cytokines; addition of the antiCD52 mAb alemtuzumab to cyclophosphamide chemotherapy synergistically increased cancer cell death and macrophagemediated elimination of leukaemia cells 139 .
Approaches to targeting macrophages A number of potential strategies to target macrophages in anticancer therapy are being explored (FIG. 4; TABLE 2 ). In general, macrophagecentred therapeutic approaches are aimed either at inhibiting the localization of these cells at tumour sites and their functions related to the pro motion of tumour progression, or at activation of their antitumour activities.
Targeting recruitment and localization. As discussed previously, the mediators involved in regulating macro phage recruitment to tumours are diverse and include chemokines, complement components, CSF1, and VEGF. Chemokines have long been implicated in macro phage accumulation within tumours 11, [15] [16] [17] 19, 27, 140 . The fact that multiple chemokines and chemokine receptors are involved in phagocyte chemotaxis ('robustness' and redundancy of the system), and that individual chemo kines act on multiple cell types (resulting in less efficient inhibition of macrophage function, specifically) are challenges to translating chemokinetargeting ther apeutic strategies into clinical benefit in patients with inflammatory and neoplastic diseases. Specific inhib ition of CCL2 with antibodies has been shown to reduce tumour growth and dissemination in different experi mental models of prostate, breast, lung or liver cancer, or melanoma; when administered in combination with chemotherapy, antiCCL2 antibodies improved the efficacy of treatment [141] [142] [143] [144] [145] . In a mouse model of breast cancer, however, withdrawal of antiCCL2 treatment has also been associated with a rebound effect, with increased mobilization of bonemarrow monocytes as well as infiltration of these cells into tumours, thus accelerating the development of lung metastasis 146 . Nevertheless, antibodies selectively targeting CCL2 have entered phase I and II clinical testing [147] [148] [149] (TABLE 2) .
In a phase I trial, the antiCCL2 antibody carlumab (CNTO 888) showed preliminary antitumour activity in patients with advancedstage solid tumours, and was well tolerated 144 . No responses were observed, how ever, in a phase II study of this agent in patients with castration resistant prostate cancer 147 . Combinations of carlumab with conventional chemotherapy have been studied in patients with solid tumours in a phase Ib clini cal trial (TABLE 1) ; good safety profiles were observed, but with no objective tumour responses 149 . The feasibility of combining PF04136309, a novel oral CCR2 small molecule antagonist, with conventional chemotherapy in patients with locally advanced pancreatic adeno carcinoma who are not eligible for surgery has been demonstrated in a phase 1b clinical trial 150 . In this study, patients received FOLFIRINOX (5fluorouracil, folinic acid, irinotecan, and oxaliplatin) alone, or in combi nation with PF04136309. Patients in the latter group did not experience worse toxicity than those receiving chemo therapy alone, and 16 of 33 imagingevaluated patients had partial tumour responses (49%), with 32 patients (97%) having local stable disease (compared with no objective responses, but four stable disease responses (80%), in five evaluable patients treated with chemotherapy only) 150 . The chemokine CCL5 has been reported to be responsible for the functional skewing of TAMs toward a protumour phenotype 151 . At tumour sites CCL5 is usually produced by cancer cells and macrophages, but in this study 151 , CD4 + and CD8 + lymphocytes were the major sources of CCL5 within CRC liver metastases. Maraviroc, an antagonist of CCR5, the cognate receptor for CCL5, is approved as a treatment for patients with AIDS. In a small cohort of patients with advancedstage CRC, treatment with maraviroc has been associated with biological and clinical responses 151 . Thus, targeting of the CCL5-CCR5 axis deserves further investigation, given that activation of this pathway is well established, for example, in the pathogenesis of breast cancer 140 .
Inhibiting the CSF-1-CSF-1R axis. CSF1R is exclu sively expressed by cells of the monocytic lineage and, therefore, is an obvious target to enable interference with TAMs directly, or indirectly via effects on TAM precursor cells. Indeed, CSF1 is the major growth and differentiation factor for cells of the monocytemacrophage lineage, and is abundantly expressed by sev eral tumour types 1, 6 . Thus, the CSF1-CSF1R axis has been extensively investigated in tumour models and is paradigmatic of the TAM-cancer cell interaction 6, [152] [153] [154] . High CSF1 or CSF1R expression levels in the tumour or peritumoural tissue have been associated with poor patient survival in different malignancies, such as CHL, breast cancer, and hepatocellular carcinoma 155, 156 . As a receptor tyrosine kinase, CSF1R is an attractive therapeutic target (FIG. 4) , and a number of small molecule and antibody antagonists have been developed and tested in preclinical models 33, 89, 154, 157, 158 . For example, the humanized mAb emactuzumab (RG7155) binds to CSF1R and prevents receptor dimerization, thereby abrogating binding to dimeric CSF1 and activation of signalling 158 . In one study, treatment of mice with emactuzumab reduced TAM densities (owing to both reduced numbers of TAMs and circulating monocytes) and increased the CD8 + :CD4 + Tcell ratio in tumour samples, compared with those seen in mice treated with a control antibody 158 ; the same effects were observed in a comparison of pre treatment and post treatment biopsy samples from patients with various solid malignancies, who were included in a phase I clini cal trial performed as part of the same study 158 (TABLE 2) . Notably, particularly promising signs of clinical activity were seen in patients with diffuse type tenosynovial giantcell tumour, a rare neoplasia characterized by overexpression of CSF1R 158 . Thus, a doseescalation and doseexpansion study was performed in patients with this disease 159 , with 26 of 28 patients (93%) achieving objective responses; no doselimiting toxicities were observed, although com mon adverse events included facial oedema, asthenia, and pruritus 159 . Pexidartinib (PLX3397), a small molecule CSF1R inhibitor that can be administered orally, also induced clinical regression in patients with teno synovial giantcell tumours 160 (TABLE 2) , thus con firming the validity of TAMs as a therapeutic target in this disease.
Pexidartinib is able to penetrate the blood-brain bar rier and has been tested in a phase II study in patients with recurrent glioblastoma 161 . The drug was well toler ated and, as proofofprinciple of its activity, circulating CD14 dim /CD16
+ monocyte numbers were reduced after treatment; however, no objective responses were reported and the primary end point of 6month progression free survival was met only in a minority (8.6%) of the 37 patients treated 161 . Clearly, the potential of these inhibitors needs to be maximized via use of rational combination therapy approaches.
Radiotherapy is known to increase the extent of macrophage infiltration into irradiated tissues, and this response can be detrimental to the therapeutic response 37, 162 . In preclinical mouse xenograft models of intracranial human glioblastoma, radio therapy has been demonstrated to increase CSF1 expression and the degree of tumour infiltration by myeloid cells 163 . In this model, treatment with pexidartinib potentiated the therapeutic effects of radiotherapy, suggesting that the effectiveness of radiotherapy in patients with glioblastoma can be improved by combination with CSF1R inhibition 163 . In a syngeneic mouse model of BRAF V600E driven melanoma, pexidartinib also improved the anti tumour efficacy of adoptive celltransfer immunotherapy by inhibiting the intratumoural accumulation of immuno suppressive macrophages 164 . Another smallmolecule CSF1R inhibitor, BZL945, has been shown to attenuate the progression of gli oma and improve survival in preclinical models 33 . Interestingly, CSF1R blockade with this agent did not result in depletion of TAM numbers, but instead contributed -together with glioma derived factors (GMCSF and IFNγ) -to 'reeducation' of macro phages from a protumour M2like phenotype to an antitumour M1like effector cell type 33 . Of note, an analysis of glio blastomas recurring in mice after CSF1R inhibition with BZL945 has revealed an inter play between cancer cells and micro environmental fac tors. Specifically, IL4 reprogrammes macrophages to the M2like phenotype and, via STAT6 and NFAT sig nalling, results in production of IGF1; the IGF1 secreted by these cells signals via IGF1R on tumour cells, caus ing activation of the PI3K pathway 165 . Accordingly, combined inhibition of IGFR1 or PI3K in tumour cells and CSF1R in macro phages resulted in prolongation of survival durations in this mouse model 165 . In a mouse model of ovarian cancer, the CSF1R inhibitor GW2580 decreased the numbers of tumour infiltrating M2like macrophages when administered at the late stages of disease (after peritoneal dissemina tion) 166 . This treatment approach dramatically reduced ascites volume, and induced normalization of the dis organized peritoneal vasculature 166 . These preclinical findings indicate that some therapeutic biological effects could be expected even in patients with advancedstage tumours. GW2580 treatment also enhanced the activ ity of gemcitabine in a transgenic model of gemcit abineresistant pancreatic ductal adenocarcinoma 167 . Mechanistically, GW2580 reduced tumour infiltration by macrophages that contribute to chemoresistance in this model by upregulating expression of the gemcit abinemetabolizing enzyme cytidine deaminase in the cancer cells 167 . These findings suggest that treatment tar geting macrophages could be a complementary strategy to enhance the efficacy of conventional chemotherapy. Along these lines, in a transgenic mouse model of mam mary adenocarcinoma, paclitaxel based chemotherapy resulted in upregulated production of CSF1, IL34 (another cytokine that signals via CSF1R), and the chemokine CCL8; blockade of the CSF1-CSF1R axis, using either an antiCSF1 antibody or a CSF1R inhib itor, enhanced the therapeutic efficacy of paclitaxel, inhibited metastasis, and increased CD8 + Tcell infil tration into tumours 89 . Inhibition of the CSF1-CSF1R axis might also increase the effectiveness of other sys temic therapies. For example, in a mouse model of pros tate cancer, androgenblockade therapy induced cancer cells to express CSF1 and other cytokines that caused increased infiltration of TAMs 100 . Correspondingly, addition of CSF1R inhibitors, such as GW2580 or pexidartinib, to androgenblockade therapy resulted in more durable therapeutic responses compared with hormonal therapy alone 100 . Collectively, preclinical data strongly suggest that targeting the CSF1-CSF1R axis has the potential to complement conventional therapeutic strategies.
Evidence has been provided of the specific factors that are important for the survival and expansion of mye loid cells in tumours. For example, the nuclear receptor RORγ is expressed in myeloid cells and drives cancer related myelopoiesis in response to colonystimulating factors 168 . Importantly, ablation of RORγ expression in the myeloid compartment restrains tumour develop ment and impairs the generation of suppressive MDSCs, while also promoting M1polarization of TAMs, which is associated with antitumour activity 168 . Thus, RORγ is a potential molecular target of myeloidcellcentred anticancer therapy.
Bisphosphonates. Bisphosphonates have cytotoxic effects on myeloid cells and are used for the treatment of osteoporosis and prevention of complications associated with bone metastases. Drugs of this class inhibit the activity of farnesyldiphosphonate synthase, a key enzyme responsible for cholesterol synthesis and protein preny lation, and have high affinities for bone hydroxyapatite; accordingly, they are predominantly internalized by and result in apoptosis of bone macro phages (osteo clasts) 169, 170 . Nevertheless, tissue macrophages other than those in bone, including TAMs, have been reported to be affected by bisphosphonates 171 , in particular, by clodronate delivered in a liposomal formulation 172, 173 . Currently, bisphosphonates are used clinically in the treatment of breast cancer and other solid malignan cies, in combination with chemotherapy or hormonal therapy. In postmenopausal women with breast cancer, disease recurrence and overall mortality have been sub stantially reduced using this approach, compared with the outcomes of hormonal therapy or chemotherapy alone 174 . Moreover, clodronate has been reported to reduce the incidence of new metastases both in bone and visceral tissues in patients with breast cancer, an obser vation that points to actions unrelated to the bone meta static niche 175 . In patients with hormonetherapynaive prostate cancer with bone metastases, treatment with zoledronic acid has been associated with reduced rates of skeletalrelated events and improved progression free survival durations 174 . The relative importance of targeting macrophages, particularly those in the bone metastatic niche, versus modifying bone resistance to osteolysis in the clinical activity of bisphosphonates remains to be assessed.
Trabectedin. As discussed, trabectedin, which was originally developed as an antiproliferative agent, can partially deplete circulating monocyte and TAM popu lations 87, 88 . The studies that revealed these effects stemmed from the clinical observation of delayed, per sistent responses to trabectedin in patients with cancer. The monocyte depletion induced by this agent includes the monocytic component of MDSCs (MMDSCs) 87 . Trabectedin has been shown to activate a TRAIL dependent pathway of apoptosis 87 (FIG. 4) ; monocytes are exquisitely sensitive to TRAIL because, unlike other leukocyte subsets (particularly neutrophils), they express very low levels of TRAIL decoy receptors 176 . In mouse tumour models and in human sarcoma speci mens, trabectedininduced reductions in TAM density are associated with decreased angiogenesis 87 . These observations raise the question as to whether the com bination of trabectedin with antiangiogenic agents and/or immunecheckpoint inhibitors might increase the effectiveness of treatment.
Functional activation of TAMs. Microbial prepara tions and microorganismderived molecules (such as bacterial muramyldipeptide) prime macrophages for tumour cytotoxicity and have undergone clinical testing in this context 177 . Intravesical Bacillus CalmetteGuérin (BCG) is the only remainder from the bacterial era of immunotherapy, and is used in the treatment of recur rent bladder carcinoma. In addition to, or in concert with microbial moieties, such as lipopolysaccharide, IFNγ is a classic inducer of macrophage M1 polariza tion and killing of tumour cells 10 . The therapeutic utility of this cytokine has been investigated in patients with ovarian cancer; with the aim of avoiding unwarranted systemic macro phage activation, IFNγ was adminis tered intraperitoneally, first in women with advanced stage ovarian cancer, and subsequently to those with minimal residual disease 178, 179 . Intraperitoneal IFNγ resulted in activation of tumour cytotoxicity and clinical responses 178, 179 . Whether the potential of IFNγ immuno therapy has been fully exploited under these conditions remains unclear.
A more specific, although unexpected, approach to targeting macrophages was discovered after admin istration of an agonistic antiCD40 antibody to mice with pancreatic cancer 180 . In this setting, alternatively activated, M2like macrophages in the tumour micro environment were reeducated towards an M1like phenotype, and acquired antigenpresenting capabil ities, leading to reestablishment of tumour immune surveillance and shortterm reductions in tumour volumes 180 . This preclinical evidence spurred phase I clinical trials to test a fully humanized antibody CD40 agonist (CP870,893) in combination with chemother apy 181 (TABLE 2) . In patients with advancedstage pancre atic cancer, combined treatment with CP870,893 and gemcitabine was well tolerated, with four of 22 patients achieving partial responses. The investigators noted that a decrease in 2[
18 F]fluoro 2deoxydglucose uptake on PET-CT imaging of hepatic lesions was cor related with improved survival in patients receiving the combination therapy 181 . Repolarization of proangiogenic and immuno suppressive M2like macrophages towards the anti tumour M1like phenotype has also been achieved in mice via expression of antiangiogenic and immuno modulatory protein histidinerich glycoprotein (HRG) 182 . This effect of HRG was dependent on downregulation of placenta growth factor (PlGF) in macrophages, supporting the evaluation of PlGFblockadebased strategies as anti cancer therapies 182 . In addition, a modified form of vitaminD binding protein, EF022, is undergoing early clinical evaluation (TABLE 2) , based on evidence of effects on macrophage activation 183 . ADCC and ADCP are amenable to therapeutic strat egies capitalizing on the effector function of TAMs. However, enhancement of macrophagedependent ADCP via interference with the inhibitory CD47-SIRPα pathway might involve mechanisms that lie beyond pure activation of TAM effector function. In a mouse xenograft model of glioblastoma, in which the M1:M2 TAM ratio has prog nostic significance, ADCP elicited by antiCD47 antibody therapy resulted in functional skewing of mouse macro phages towards an M1 phenotype, thus contributing to antitumour immune responses 129 . In a preclinical model of pancreatic cancer, crosstalk between B cells and FcRγ + TAMs has been shown to pro mote M2like macrophage programming via BTK-PI3Kγ signalling, and was implicated in tumour progression; administration of a PI3Kγ inhibitor or the BTK inhibitor ibrutinib reset macrophages toward a M1like phenotype that promoted CD8 + Tcell cytotoxicity and curbed pan creatic ductal adenocarcinoma growth 184 . This strategy is currently under clinical evaluation in combination with gemcitabine-nab paclitaxel chemotherapy in patients with pancreatic cancer 119 (TABLE 2) .
The use of nonsteroidal antiinflammatory drugs (NSAIDs), particularly aspirin, is associated with pro tection against the occurrence of many tumour types, as well as against the development of metastasis in patients with cancer [185] [186] [187] . Prostaglandin E 2 (PGE 2 ) has wellestablished immunosuppressive effects (FIG. 2) , for instance, on dendritic cells, and is known to promote the development of MDSCs 188 . Intriguingly, PGE 2 has been shown to cause transactivation of CSF1R via Src family kinase signalling in mouse macrophage cell lines, thus enhancing their migratory capacity (and acting syner gistically with CSF1 in inducing macrophage migra tion) 189 . Prostaglandins (such as PGE 2 ) have also been reported to be involved in the M2like polarization of macrophages, in part, through activation of the cAMP pathway 190, 191 . Thus, it is tempting to speculate that tar geting the tumourassociated myeloid cells plays a major part in the protective function of NSAIDs against both primary cancer and metastasis.
Conclusions
Cells of the monocyte-macrophage lineage are an essen tial inflammatory component of the ecological tumour niche, and have key roles in regulating disease progres sion. Progress has been made in defining the molecular landscapes and mechanisms of macrophage differenti ation and diversity in tissues, including tumours 21, 24, 192 . Macrophage diversity relates to the presence of TAMs with different functional profiles within tumours, which is often dictated by hypoxia. Current general paradigms relating to TAMs reflect assessments of these hetero geneous cells at the total population level. Deconvoluting TAM heterogeneity at the singlecell level and integrat ing such information into functional studies are impor tant challenges that must be addressed in the future, in order to provide new insights into cancerrelated inflammation.
Macrophages can exert dual influences on the effects of conventional cytoreductive therapies and radiother apy. Moreover, TAMs contribute to creating an immuno suppressive tumour micro environment through multiple routes, including triggering of inhibitory immune check points in T cells. Determining whether TAMs are pre dictive biomarkers that guide the use of cytoreductive therapies and immunotherapy, and thereby contribute to personalized patient care, will be important.
Macrophagecentred therapeutic approaches are entering the clinical arena (TABLE 2) . These strategies include blockade of the tumourpromoting activities of TAMs, and exploitation of macrophage anti tumour effector functions (including ADCC, ADCP, and M1like phenotypes). Macrophagetargeting strat egies can per se result in therapeutic benefits; however, our tenet is that macrophagedirected therapeutics are best used to complement conventional cytoreductive therapies, angiogenesis inhibitors, and immunotherapy.
